Gastrointestinal Stromal Tumor Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Daiichi Sankyo, Novartis, Takeda, Plexxikon

Posted on
by

Gastrointestinal Stromal Tumor Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Daiichi Sankyo, Novartis, Takeda, Plexxikon
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 25+ key pharma and biotech companies are working on 28+ pipeline drugs in the Gastrointestinal Stromal Tumor therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Gastrointestinal Stromal Tumor Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Gastrointestinal Stromal Tumor Market. 

The Gastrointestinal Stromal Tumor Pipeline report embraces in-depth commercial, regulatory, and Gastrointestinal Stromal Tumor clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Gastrointestinal Stromal Tumor drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Gastrointestinal Stromal Tumor Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Gastrointestinal Stromal Tumor treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Gastrointestinal Stromal Tumor therapies segmented into early-stage, mid-stage, and late-stage clinical development.

  • It outlines the major Gastrointestinal Stromal Tumor companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Gastrointestinal Stromal Tumor drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Gastrointestinal Stromal Tumor therapeutic market.

Gastrointestinal Stromal Tumor Therapeutics Landscape

There are approx. 25+ key companies developing therapies for Gastrointestinal Stromal Tumors. Currently, Jiangsu Hengrui Medicine is leading the therapeutics market with its Gastrointestinal Stromal Tumors drug candidates in the most advanced stage of clinical development.

Gastrointestinal Stromal Tumor Companies Actively Working in the Therapeutic Market Include:

  • Jiangsu Hengrui Medicine

  • Daiichi Sankyo Company

  • Cogent Biosciences

  • Advenchen Laboratories

  • Chia Tai Tianqing Pharmaceutical Group

  • AB Science

  • Immunicum AB

  • Novartis

  • Bristol-Myers Squibb

  • Hanmi Pharmaceutical Company Limited

  • GlaxoSmithKline

  • Ascentage Pharma

  • Takeda

  • Array BioPharma

  • Plexxikon

  • Arog Pharmaceuticals

  • Xencor, Inc.

  • DNAtrix, Inc.

  • Onyx Pharmaceuticals

  • Exelixis

  • Allarity Therapeutics

  • Theseus Pharmaceuticals

  • IDRx, Inc.

  • Allarity Therapeutics

And Many Others

Emerging and Marketed Gastrointestinal Stromal Tumor Drugs Covered in the Report Include:

  • Famitinib: Jiangsu Hengrui Medicine

  • Nilotinib: Novartis

  • THE-630: Theseus Pharmaceuticals

  • DS 6157: Daiichi Sankyo Company

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Gastrointestinal Stromal Tumor Companies Working in the Market @

https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight

Analysis of Emerging Gastrointestinal Stromal Tumor Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

The Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Gastrointestinal Stromal Tumor Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Gastrointestinal Stromal Tumor Treatment Patterns

4. Gastrointestinal Stromal Tumor – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Gastrointestinal Stromal Tumor Late Stage Products (Phase-III)

7. Gastrointestinal Stromal Tumor Mid-Stage Products (Phase-II)

8. Gastrointestinal Stromal Tumor Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Gastrointestinal Stromal Tumor Discontinued Products

13. Gastrointestinal Stromal Tumor Product Profiles

14. Major Gastrointestinal Stromal Tumor Companies in the Market

15. Key Products in the Gastrointestinal Stromal Tumor Therapeutics Segment

16. Dormant and Discontinued Products

17. Gastrointestinal Stromal Tumor Unmet Needs

18. Gastrointestinal Stromal Tumor Future Perspectives

19. Gastrointestinal Stromal Tumor Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Sickle Cell Disease Market

“Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Sickle Cell Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Sickle Cell Disease market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/